FORT LAUDERDALE, Fla., Oct. 14 /PRNewswire-FirstCall/ -- Imaging Diagnostic Systems, Inc., a pioneer in laser optical breast cancer imaging systems, announced today that its distributor, Laszlo Meszaros of Kardia Hungary Kft., has purchased the first CT Laser Mammography (CTLM(R)) system for Budapest, Hungary.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040412/IMDSLOGO )
The CTLM system will be installed at the new MeDoc HealthCare Center (MDHC) located in Budapest, in collaboration with Dr. Maria Gergely/Chief Radiologist of Uzsoki Hospital. "I am very excited to have this opportunity to provide my patients with more comprehensive imaging and I hope to find more cancers in the dense breast patients where it is most difficult to image with today's current technologies," commented Dr. Gergely.
MDHC is a new privately operated medical center that focuses on the latest detection for cancer by offering its patients the most current and cutting edge imaging equipment.
Dr. Andras Vertes, CEO/MDHC commented, "I am looking forward to working with the CTLM system and believe it will fit in very well with our other modalities."
"We will continue to focus on obtaining recognition for the CTLM system in the International markets through our distribution network, reference sites, Imaging Conferences and Symposiums in hopes to generate additional sales," quoted Linda B Grable/CEO of Imaging Diagnostic Systems.
About Imaging Diagnostic Systems, Inc.
Imaging Diagnostic Systems, Inc. has developed a revolutionary breast imaging device to aid in the detection and management of breast cancer. The CTLM system is a breast imaging system that utilizes patented continuous wave laser technology and computer algorithms to create 3-D images of the breast. The procedure is non-invasive, painless, and does not expose the patient to ionizing radiation or painful breast compression. CTLM is designed to be used in conjunction with mammography. It reveals information about blood distribution in the breast and may visualize the process of angiogenesis, which usually accompanies tumor growth.
Imaging Diagnostic Systems is currently collecting data from clinical sites for the future filing of an FDA Premarket Approval (PMA) for the Computed Tomography Laser Mammography system to be used as an adjunct to mammography. The FDA has determined that the Company's clinical study is a non-significant risk (NSR) investigational device study under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The CTLM system is limited by United States Federal Law to investigational use only in the United States. The CTLM system has received other registrations including CE, CMDCAS Canadian License, China SFDA, UL, ISO 9001:2000, ISO 13485:2003 and FDA export certification.
For more information, visit our website: http://www.imds.com .
As contemplated by the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future, anticipated, or projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates or predictions of future results or events and there can be no assurance that actual results or events will not materially differ from expectations. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company's filings with the Securities and Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.
CONTACT: Deborah O'brien of Imaging Diagnostic Systems, Inc.,
+1-954-327-3216, obrien@imds.com
Web site: http://www.imds.com/
